Clopidogrel-PPI Interaction More Relevant in Noncarriers of CYP2C19 Loss-of-Function Gene

A small pharmacodynamic study has suggested that the interaction between clopidogrel and proton-pump inhibitors (PPIs) may be more important in patients who do not carry any CYP2C19 loss-of-function alleles.

Presenting the results at the European Society of Cardiology (ESC) 2010 Congress last week, Dr Jen-Kuang Lee (National Taiwan University, Taipei) said: "We found noncarriers of the CYP2C19 loss-of-function alleles were more susceptible to the effects of the PPI-clopidogrel interaction than carriers were."

Lee explained to heartwire that as PPIs and clopidogrel are both metabolized by the CYP2C19 enzyme, it would be of interest to find out whether individuals carrying CYP2C19 loss-of-function genes were particularly affected by the PPI-clopidogrel interaction. But bizarrely, they found the opposite result.

More at Medscape